HC Wainwright Issues Positive Forecast for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, May 5th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($1.07) for the quarter, up from their prior forecast of ($1.42). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.93) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($4.67) EPS, Q1 2027 earnings at ($1.27) EPS, Q2 2027 earnings at ($1.19) EPS, Q3 2027 earnings at ($1.29) EPS and Q4 2027 earnings at ($1.25) EPS.

Other equities research analysts have also recently issued reports about the stock. Evercore reissued an “outperform” rating and issued a $74.00 price target on shares of CRISPR Therapeutics in a research report on Friday, February 13th. TD Cowen boosted their price target on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Monday, April 20th. Citigroup boosted their price target on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Needham & Company LLC boosted their price target on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $64.82.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $55.08 on Thursday. CRISPR Therapeutics has a 1-year low of $33.50 and a 1-year high of $78.48. The stock has a market cap of $5.31 billion, a PE ratio of -8.86 and a beta of 1.74. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 13.32. The firm has a fifty day moving average price of $52.43 and a 200 day moving average price of $54.51.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The company had revenue of $1.46 million during the quarter.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CRSP. Allspring Global Investments Holdings LLC grew its position in CRISPR Therapeutics by 11.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,932 shares of the company’s stock worth $290,000 after buying an additional 605 shares during the period. Independent Financial Group LLC acquired a new position in CRISPR Therapeutics during the first quarter worth about $292,000. D.A. Davidson & CO. grew its position in CRISPR Therapeutics by 5.9% during the first quarter. D.A. Davidson & CO. now owns 6,324 shares of the company’s stock worth $301,000 after buying an additional 353 shares during the period. Canal Insurance CO acquired a new position in CRISPR Therapeutics during the first quarter worth about $1,670,000. Finally, CAP Partners LLC acquired a new position in CRISPR Therapeutics during the first quarter worth about $205,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Naimish Patel sold 3,150 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $48.26, for a total value of $152,019.00. Following the completion of the sale, the insider directly owned 13,143 shares of the company’s stock, valued at approximately $634,281.18. This represents a 19.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 10,020 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total transaction of $468,735.60. Following the completion of the sale, the chief executive officer directly owned 255,501 shares of the company’s stock, valued at $11,952,336.78. The trade was a 3.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 51,828 shares of company stock valued at $2,578,097. Insiders own 4.30% of the company’s stock.

Key Headlines Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler initiated/confirmed a Buy on CRISPR, giving investors a fresh constructive analyst view that can attract buyers. Crispr Therapeutics AG (CRSP) Gets a Buy from Piper Sandler
• Positive Sentiment: Chardan Capital reiterated a Buy on CRSP, reinforcing institutional support and signaling confidence in the company’s mid‑term value drivers. Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)
• Positive Sentiment: Analysts and commentators point to commercial momentum for Casgevy and upcoming H2 in‑vivo catalysts as a buy case—coverage highlighting revenue growth prospects supports upside expectations. Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case
• Positive Sentiment: Management will present at the Bank of America Global Healthcare Conference next week — a high‑visibility event that can drive renewed investor interest and provide updated commercial/programmatic color. CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
• Neutral Sentiment: Coverage is mixed — a Globe & Mail roundup highlights conflicting analyst views across healthcare names (including CRSP), underscoring varied risk/reward perceptions among firms. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: HC Wainwright published FY2027 EPS estimates for CRSP (continuing negative EPS consensus), keeping longer‑term profitability expectations uncertain. HC Wainwright FY2027 Estimates
• Negative Sentiment: Q1 report showed a wider-than-expected loss and revenue miss, which pressured shares — although management highlighted Casgevy sales growth and strengthened cash after financing, the near‑term top‑line shortfall is a clear downside catalyst. CRISPR Therapeutics’ Q1 Loss Wider Than Expected, Sales Miss Estimates
• Negative Sentiment: Brookline Capital trimmed its FY2028 EPS forecast, signaling some analyst caution on longer-term profitability and valuation assumptions. Brookline Capital Lowers FY2028 EPS Estimate

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.